SPOT-mRNA03

· Shanghai Siponuoyin Biotechnology Co Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SPOT-mRNA03, covering 2025-09-23 to 2025-09-23. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Dystrophin Expression of SPOT-mRNA03 in Duchenne Muscular Dystrophy (DMD) Patients [EARLY_Phase 1]